History

Raloxifene is a fully FDA-approved prescription drug, developed by Eli Lilly and marketed as Evista (now also generic). The FDA first approved it in 1997 for the prevention of postmenopausal osteoporosis, then in 1999 for the treatment of postmenopausal osteoporosis. In 2007 the indication expanded to reduction of invasive breast-cancer risk in two postmenopausal populations — women with osteoporosis and women at high risk of invasive breast cancer. It is a second-generation SERM and was never approved to treat existing breast cancer (that is tamoxifen and aromatase-inhibitor territory), only risk reduction in the labeled populations, and it is not indicated in men.

Raloxifene, sold as Evista, is an oral, once-daily selective estrogen receptor modulator (SERM) — a legitimate, well-characterized prescription drug. It is important to be precise about what it is: raloxifene is not a peptide, not an aromatase inhibitor (which is a different anti-estrogen mechanism), and not an anabolic steroid. It is a benzothiophene that binds the estrogen receptor and behaves as an estrogen agonist in some tissues (bone, lipids) and an antagonist in others (breast, uterus). In postmenopausal medicine it has a strong, repeatedly published evidence base for bone and breast-cancer-risk endpoints. In bodybuilding circles it is used off-label to block estrogen receptors in breast tissue — a practice that is unapproved, thinly studied in men, banned in sport, and carries real clotting and stroke risk. This page is educational and harm-reduction oriented; it contains no dosing, cycles, stacks, or post-cycle protocols, and no sourcing information.

What it is

Raloxifene is a second-generation SERM and a benzothiophene derivative. It binds estrogen receptors (ERα/ERβ) and acts as a tissue-selective agonist or antagonist depending on the tissue and the co-regulators present. In bone it is an estrogen agonist — it suppresses osteoclast-mediated bone resorption, which increases or preserves bone mineral density (BMD) — and it lowers LDL cholesterol. In breast and uterine (endometrial) tissue it is an estrogen antagonist.

This tissue selectivity is the key distinction from older anti-estrogens. Unlike tamoxifen, raloxifene does not stimulate the endometrium, so it does not carry tamoxifen’s endometrial-cancer signal. And unlike aromatase inhibitors (anastrozole, letrozole, exemestane), which lower estrogen by blocking the enzyme that makes it, raloxifene does not reduce circulating estradiol — it blocks the receptor in target tissues. The approved product is 60 mg raloxifene HCl taken once daily.

The claims

Medically, raloxifene is used in postmenopausal women for the prevention and treatment of osteoporosis, and for reduction of invasive breast-cancer risk in the two labeled postmenopausal populations (women with osteoporosis and women at high risk of invasive breast cancer). It is used in women and is not indicated in men.

In the PED context (off-label, illicit, and unapproved), male anabolic-androgenic steroid users take SERMs — raloxifene, tamoxifen, clomiphene — as estrogen-receptor blockers in breast tissue. The most common stated goals are to manage or attempt to reverse gynecomastia driven by aromatization of high-dose androgens, and as part of “post-cycle” attempts to restart endogenous testosterone (SERMs can raise gonadotropins and testosterone in men). Raloxifene is sometimes preferred over tamoxifen specifically for breast-tissue gynecomastia management. None of this is an approved use, the evidence base in men is thin, and no doses, cycles, stacks, or PCT protocols are given here.

What the evidence actually shows

The postmenopausal evidence base is large and robust, and it is honest about raloxifene’s limits.

Vertebral fractures (MORE trial): In 7,705 postmenopausal women with osteoporosis over 3 years, raloxifene increased spine and femoral-neck BMD and reduced vertebral (spine) fracture risk — for example, 6.6% in the 60 mg arm versus 10.1% on placebo at 36 months (Ettinger et al., JAMA 1999).
No proven hip or non-vertebral fracture benefit: The robust fracture evidence is for vertebral fractures only. In MORE, non-vertebral fracture risk did not differ significantly (RR ~0.9). Raloxifene has not been shown to reduce hip or other non-vertebral fractures — an important limitation versus bisphosphonates.
Breast-cancer prevention (STAR / NSABP P-2): In 19,747 high-risk postmenopausal women, raloxifene was compared with tamoxifen. In the updated analysis, raloxifene was about 76% as effective as tamoxifen at preventing invasive breast cancer (risk ratio raloxifene:tamoxifen ≈ 1.24), but with fewer thromboembolic events (RR ~0.75) and fewer endometrial/uterine cancers (RR ~0.55) than tamoxifen (Vogel et al., Cancer Prev Res (Phila) 2010).
Cardiovascular (RUTH trial): In 10,101 postmenopausal women with or at high risk for coronary heart disease (median ~5.6 years), raloxifene did not reduce coronary events (HR 0.95). It did reduce invasive breast cancer (HR 0.56) and vertebral fracture, but it was associated with a significant increase in fatal stroke (HR ≈ 1.49) and increased venous thromboembolism (HR ≈ 1.44). The net: no cardioprotection, and real vascular harms (Barrett-Connor et al., NEJM 2006).

On PED use specifically: the human evidence above comes from postmenopausal women, not healthy male athletes. There are no high-quality trials validating raloxifene for estrogen-receptor blockade or testosterone recovery in male steroid users, so efficacy and safety claims for that use are largely extrapolated and poorly studied.

Legal and regulatory status

US — prescription (Rx) drug. Raloxifene (Evista) is legal only with a valid prescription. It is not a controlled substance — SERMs and aromatase inhibitors are not scheduled. Buying or selling it without a prescription, or as a non-pharmaceutical “research chemical,” is unlawful, and such products are unregulated and unverified.

For legal clarity, it helps to contrast the compounds that come up alongside it in the PED context:

Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids — Schedule III controlled substances under the US Controlled Substances Act.
DNP (2,4-dinitrophenol) is NOT approved for human consumption. The FDA banned it for weight loss in the 1930s and deems it unfit for human consumption; it has a long history of fatal poisonings, is sold illegally as a “fat burner,” and has no antidote.
T3 (liothyronine) and insulin are legitimate prescription drugs, not controlled substances, but are dangerous when misused for body composition (see Safety).

Anti-doping (WADA 2026 Prohibited List, in force 1 January 2026). SERMs, including raloxifene, are prohibited at all times (in- and out-of-competition) under Section S4, “Hormone and Metabolic Modulators.”

S4.2 Anti-estrogenic substances — raloxifene, tamoxifen, clomifene, toremifene, cyclofenil, fulvestrant, ospemifene, and bazedoxifene. This is where raloxifene sits.
S4.1 Aromatase inhibitors — anastrozole, letrozole, exemestane, and others.
S4.4 Metabolic modulators — includes insulins and insulin-mimetics (specifically S4.4.2).
S1 Anabolic agents — mesterolone, fluoxymesterone, and other anabolic-androgenic steroids.

Two notes on the 2026 list. First, the 2026 S4 additions are α-naphthoflavone (7,8-benzoflavone) as an aromatase inhibitor (S4.1) and BAM15 as an AMPK activator (S4.4) — both flagged as turning up in supplements and “research chemicals.” Second, on a point that is widely misstated: DNP is NOT an S4 substance. It is captured under S0 (Non-Approved Substances) and is prohibited at all times. T3 (liothyronine) is not specifically named on the WADA list, though its misuse is medically dangerous.

Safety

Raloxifene has well-characterized harms, and the genuinely catastrophic acute dangers in this PED landscape belong to the compounds users combine with it.

Raloxifene-specific harms (the real ones):

Venous thromboembolism (VTE) — the most important serious risk. Raloxifene increases the risk of deep-vein thrombosis (DVT) and pulmonary embolism (PE), highest in the first months of use. Women with active or past VTE should not take it. This is a labeled Warning in the EVISTA label (not an FDA black-box/boxed warning).
Fatal stroke. RUTH showed an increased risk of fatal stroke in women already at high cardiovascular risk, and the label carries a corresponding stroke-death warning. Raloxifene does not prevent heart disease despite favorable LDL effects.
Other: hot flashes, leg cramps, and peripheral edema. Because of clot risk, it should be stopped before and during prolonged immobilization (surgery, long travel).

Class and PED-context dangers (covered honestly):

DNP — the most lethal item here. It uncouples mitochondrial oxidative phosphorylation, so cellular energy is released as runaway heat. This causes fatal hyperthermia (core temperature can climb toward ~44 °C / 111 °F), tachycardia, profuse sweating, metabolic acidosis, multi-organ failure, and cardiac arrest. There is no antidote. Deaths occur even at “fat-loss” doses, often with rapid deterioration and frequently despite full hospital care. DNP kills people; it is categorically unsafe for human consumption and should never be ingested.
Insulin (misused for body composition): can cause profound, lethal hypoglycemia — seizures, irreversible brain injury, coma, and death — especially without medical monitoring and carbohydrate rescue. It is a well-documented cause of death among bodybuilders misusing metabolic drugs.
Aromatase inhibitors (used to crush estrogen): driving estradiol too low harms bone mineral density (osteoporosis and fracture risk) and worsens the lipid profile and cardiovascular risk, with joint pain and mood/libido effects.
SERMs generally (raloxifene, tamoxifen): thromboembolic clots (DVT/PE, stroke) are the signature serious risk. Tamoxifen additionally carries endometrial-cancer risk (raloxifene does not) and reported visual disturbances.
T3 (liothyronine): inducing a hyperthyroid state for fat loss causes cardiac strain (tachyarrhythmias, atrial fibrillation), bone loss, and muscle catabolism, and can suppress the endogenous thyroid axis, sometimes requiring prolonged recovery.

Bottom line

Raloxifene is a legitimately approved, well-characterized SERM for postmenopausal bone and breast-cancer-risk indications — not a peptide, not an aromatase inhibitor, and not an anabolic steroid. Its defining serious risks are blood clots and fatal stroke, and it has no proven hip-fracture or cardiovascular benefit. Its non-medical use in men is off-label and under-evidenced, and it is banned in sport at all times under WADA S4.2. The genuinely catastrophic acute dangers in the surrounding PED-support landscape are DNP (no antidote, fatal hyperthermia) and insulin (lethal hypoglycemia).

Evidence grade: Strong human.